Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC.BCLI · Entity 7869 | COO and Chief Medical Officer | March 06, 2022 | March 15, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRAINSTORM CELL THERAPEUTICS INC.
Report date March 06, 2022 · Filed March 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 223,310 |
Reported balance
After 2022-03-06 transaction · row 1
1 source rowRow 1 · 2022-03-06 · Grant · Acquired 35,885 · Balance 223,310 F1: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of March 6, 2022, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of March 6, 2022, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2022 Filed Mar 15, 2022 00:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 35,885 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-033496 · tm228679-1_4seq1.xml · nonDerivative · entry 1 Kern Ralph Dr. · CIK 0001699684 · COO and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,310 F1 · shares: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of March 6, 2022, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date. Read SEC document |
| December 10, 2021 Filed Dec 11, 2021 01:05 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 35,885 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-148754 · tm2135032-9_4.xml · nonDerivative · entry 1 Kern Ralph Dr. · CIK 0001699684 · COO and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,425 F1 · shares: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of March 6, 2021, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date. Read SEC document |
| March 09, 2020 Filed Mar 13, 2020 21:01 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $7.33 | $0.00 |
DisclosureSEC source: 0001104659-20-033203 · tm2012148d1_4.xml · derivative · entry 1 Kern Ralph Dr. · CIK 0001699684 · COO and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2030-03-09 F1 · derivative.exercise_date: Option becomes vested and exercisable as to 25% of the number of shares on each of the first four anniversaries of the grant date until fully vested and exercisable on the fourth anniversary of the grant date. Read SEC document |
| March 06, 2020 Filed Mar 6, 2020 21:10 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 35,885 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-030195 · tm2011847d1_form4.xml · nonDerivative · entry 1 Kern Ralph Dr. · CIK 0001699684 · COO and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,540 F1 · shares: Shares acquired are shares of restricted stock awarded on March 6, 2020 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of the date of grant, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date. Read SEC document |
| December 24, 2019 Filed Dec 27, 2019 12:01 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 3,000 | $3.88 | $11,640.00 |
DisclosureSEC source: 0001104659-19-076291 · tm1927404-3_4.xml · nonDerivative · entry 1 Kern Ralph Dr. · CIK 0001699684 · COO and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,655 Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 22:02 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 35,885 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-013081 · tv514173_form4.xml · nonDerivative · entry 1 Kern Ralph Dr. · CIK 0001699684 · COO and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,655 F1 · shares: Shares acquired are shares of restricted stock awarded on March 6, 2019 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of the date of grant, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 20:05 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 5,000 | $3.60 | $17,997.00 |
DisclosureSEC source: 0001144204-18-015580 · tv488647_4.xml · nonDerivative · entry 1 Kern Ralph Dr. · CIK 0001699684 · COO and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,885 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.59 to $3.60, inclusive. The reporting person undertakes to provide to Brainstorm Cell Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 14:48 UTC Amendment | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 5,000 | $3.60 | $17,997.00 |
DisclosureSEC source: 0001144204-18-015759 · tv488976_4a.xml · nonDerivative · entry 1 Kern Ralph Dr. · CIK 0001699684 · COO and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,885 F2 · kind: This Form 4/A is being filed to reflect that this transaction was an open market purchase of the Issuer's securities (on March 19, 2018 this transaction was incorrectly reported on Form 4 as an acquisition pursuant to Rule 16b-3(d)). F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.59 to $3.60, inclusive. The reporting person undertakes to provide to Brainstorm Cell Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 06, 2018 Filed Mar 26, 2018 20:49 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 35,885 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-016910 · tv489540_4.xml · nonDerivative · entry 1 Kern Ralph Dr. · CIK 0001699684 · COO and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,770 F1 · shares: Shares acquired are shares of restricted stock awarded on March 6, 2018 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of the date of grant, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date. Read SEC document |
| March 06, 2017 Filed Mar 6, 2017 21:05 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantStock Option (right to buy) · Derivative | 47,847 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001144204-17-012940 · v461202_4.xml · derivative · entry 2 Kern Ralph Dr. · CIK 0001699684 · COO and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,847 Underlying: Common Stock · 47,847 shares Expires 2019-03-06 F2 · derivative.exercise_date: Option is fully vested and exercisable as of the date of grant and shall remain exercisable until the 2nd anniversary of the date of grant. Read SEC document |
| March 06, 2017 Filed Mar 6, 2017 21:05 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 35,885 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-012940 · v461202_4.xml · nonDerivative · entry 1 Kern Ralph Dr. · CIK 0001699684 · COO and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,885 F1 · shares: Shares acquired are shares of restricted stock awarded on March 6, 2017 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of the date of grant, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.